Moderna plans to prioritize new product approvals and oncology investments, as political concerns over Robert F. Kennedy Jr.'s HHS nomination weigh on vaccine stocks.

Piper Sandler lowered the firm’s price target on Moderna (MRNA) to $69 from $115 and keeps an Overweight rating on the shares. The firm notes ...

1 booster (and Moderna’s, though the TGA has not approved ... So who should get vaccinated, and when? Updating vaccines to deal with mutating viruses is not a new concept. It has been happening for ...

If you missed the early fall push for flu and COVID-19 vaccines, it’s not too late. Health officials say it’s important to get vaccinated ahead of the holidays, when respiratory bugs tend to spread ...